Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial
G Van Assche, W J Sandborn, B G Feagan, B A Salzberg, D Silvers, P S Monroe, W M Pandak, F H Anderson, J F Valentine, G E Wild, D J Geenen, R Sprague, S R Targan, P Rutgeerts, V Vexler, D Young, R S Shames
Gut Nov 2006, 55 (11) 1568-1574; DOI: 10.1136/gut.2005.089854
